JP Morgan raised the price target for the CytomX Therapeutics Inc. (NASDAQ:CTMX) stock to “an Overweight”. The rating was released on March 29, 2021. The stock was downgraded by Jefferies, who disclosed in a research note on June 01, 2020, from Buy to Hold and set the price objective to $10. In their research brief published May 14, 2020, H.C. Wainwright analysts reiterated the CytomX Therapeutics Inc. stock to Buy with a price target of $12.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.32 during the last quarter as opposed to a consensus estimate of -$0.5, which indicates the company beat its estimate by $0.18, which implies that the company surprised the market by 36.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.35. This is an average of 11 analysts’ earnings, where the high earnings per share estimate is -$0.06 and the low earnings per share estimate is -$0.52.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of CytomX Therapeutics Inc. (NASDAQ:CTMX) dipped -1.37% to close Friday’s market session at $9.36, lower as compared to yesterday’s close. The stock price fluctuated between $9.18 and $9.65 throughout the trading session with the volume trading being 3230833 shares, which represented a significant variation when compared to the three months average volume of 966.24K shares. The firm’s stock price fluctuated 2.18% within the last five trades and 21.09% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 39.29% in the last 6 months and 35.46% was added to its value over the previous 3 months. CTMX stock is trading at a margin of 14.03%, 14.37% and 24.55% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CTMX deals in the Healthcare domain. The stock is trading -39.38 percent below its 52-week high and 49.76 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -1.96. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does CytomX Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -48.40 percent and the profit margin is -32.80 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $616.92 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 6.14 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 8.75, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.30 percent of CytomX Therapeutics Inc. shares are owned by insiders, and 74.70 percent are held by financial institutions. McCarthy Sean A., the President and CEO at CytomX Therapeutics Inc. (CTMX) has sold 100,000 shares of firm on Mar 31 at a price of $7.49 against the total amount of $0.75 million. In another inside trade, McCarthy Sean A., President and CEO of CytomX Therapeutics Inc. (NASDAQ:CTMX) sold 36,000 shares of the firm on May 12 for a total worth of $0.54 million at a price of $15.00.